Loading...
EAPI logo

Euroapi S.A.ENXTPA:EAPI 株式レポート

時価総額 €130.4m
株価
€1.37
€2.9
52.8% 割安 内在価値ディスカウント
1Y-50.1%
7D7.4%
ポートフォリオ価値
​
表示

Euroapi S.A.

ENXTPA:EAPI 株式レポート

時価総額：€130.4m

Euroapi（EAPI）株式概要

Euroapi S.A.は、ヒトおよび動物用医薬品の製剤に使用される原薬および中間体の開発、製造、販売、流通を行っている。 詳細

EAPI ファンダメンタル分析
スノーフレーク・スコア
評価4/6
将来の成長3/6
過去の実績0/6
財務の健全性5/6
配当金0/6

報酬

当社が推定した公正価値より17.5%で取引されている

収益は年間78.19%増加すると予測されています

同業他社や業界と比較して、良好な取引価格

リスク分析

French市場と比較した過去 3 か月間の株価の変動


EAPI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives
GANX logo
GANXFeatured

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
View narrative
Community Contributor
US$7.6FV • 75.1% 割安 内在価値ディスカウント
5022.2%Revenue growth p.a.
3.7k
23
2
54
28d ago

Euroapi S.A. 競合他社

価格と性能

株価の高値、安値、推移の概要Euroapi
過去の株価
現在の株価€1.37
52週高値€3.57
52週安値€1.22
ベータ0.95
1ヶ月の変化4.82%
3ヶ月変化-35.32%
1年変化-50.07%
3年間の変化-86.88%
5年間の変化n/a
IPOからの変化-89.86%

最新ニュース

EAPI: Lower Demand And Portfolio Cuts Will Weigh On Future Earnings

Analysts have cut their price target on Euroapi to €1 from €2, with the change framed around more cautious assumptions despite essentially unchanged fair value, discount rate, revenue growth, profit margin and future P/E inputs in the latest update. Analyst Commentary Bearish analysts cutting the price target on Euroapi to €1 from €2 are signaling a more cautious stance around the stock, even though their core valuation inputs such as fair value frameworks, discount rate, revenue growth, profit margin and future P/E assumptions are described as essentially unchanged.

EAPI: Future Cost Controls May Unlock Upside Despite 2026 Sales Headwinds

Analysts now see Euroapi's fair value closer to €2.90, down from €3.50, aligning with a series of lower Street price targets that most recently moved from €2.50 to €2 and then to €1. Analyst Commentary The recent cuts in fair value and Street targets to around €1 to €2 signal a cautious stance from research desks, with the most recent change bringing the target to €1 and maintaining a Sell view.

EAPI: Weaker 2026 Outlook And Portfolio Cuts Will Pressure Earnings Quality

Analysts have cut their price target on Euroapi to €1 from €2, with the shift broadly tied to ongoing caution reflected in recent research commentary that maintains a Sell stance and modest adjustments to revenue growth and profit margin assumptions. Analyst Commentary Recent research updates highlight a series of price target cuts on Euroapi, with bearish analysts reducing their fair value estimates while maintaining a cautious stance on the shares.

EAPI: Weaker 2025 Guidance Will Pressure Margins And Future Earnings Quality

Analysts have cut their Euroapi price target from €2 to €1, reflecting updated assumptions that now factor in lower revenue growth expectations, much slimmer profit margins, and a significantly higher future P/E multiple. Analyst Commentary Recent price target revisions point to a cautious stance from bearish analysts, who appear focused on execution risks and the implications for Euroapi's valuation.

Recent updates

EAPI: Lower Demand And Portfolio Cuts Will Weigh On Future Earnings

Analysts have cut their price target on Euroapi to €1 from €2, with the change framed around more cautious assumptions despite essentially unchanged fair value, discount rate, revenue growth, profit margin and future P/E inputs in the latest update. Analyst Commentary Bearish analysts cutting the price target on Euroapi to €1 from €2 are signaling a more cautious stance around the stock, even though their core valuation inputs such as fair value frameworks, discount rate, revenue growth, profit margin and future P/E assumptions are described as essentially unchanged.

EAPI: Future Cost Controls May Unlock Upside Despite 2026 Sales Headwinds

Analysts now see Euroapi's fair value closer to €2.90, down from €3.50, aligning with a series of lower Street price targets that most recently moved from €2.50 to €2 and then to €1. Analyst Commentary The recent cuts in fair value and Street targets to around €1 to €2 signal a cautious stance from research desks, with the most recent change bringing the target to €1 and maintaining a Sell view.

EAPI: Weaker 2026 Outlook And Portfolio Cuts Will Pressure Earnings Quality

Analysts have cut their price target on Euroapi to €1 from €2, with the shift broadly tied to ongoing caution reflected in recent research commentary that maintains a Sell stance and modest adjustments to revenue growth and profit margin assumptions. Analyst Commentary Recent research updates highlight a series of price target cuts on Euroapi, with bearish analysts reducing their fair value estimates while maintaining a cautious stance on the shares.

EAPI: Weaker 2025 Guidance Will Pressure Margins And Future Earnings Quality

Analysts have cut their Euroapi price target from €2 to €1, reflecting updated assumptions that now factor in lower revenue growth expectations, much slimmer profit margins, and a significantly higher future P/E multiple. Analyst Commentary Recent price target revisions point to a cautious stance from bearish analysts, who appear focused on execution risks and the implications for Euroapi's valuation.

EAPI: Lower 2025 Guidance And Reduced Multiple Will Shape Return Profile

Analysts have trimmed their price target on Euroapi to €2 from €2.50, citing updated assumptions on modest revenue growth, slightly higher profit margins, and a marginally lower future P/E multiple. Analyst Commentary Recent research points to a more cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.

EAPI: Lower 2025 Outlook And Cautious Stance Will Shape Return Profile

Analysts have lowered their price target on Euroapi from €2.50 to €2, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that collectively suggest a more cautious valuation stance. Analyst Commentary Bearish analysts have recently cut their price target on Euroapi from €2.50 to €2.

EAPI: Execution Risks And Lower Outlook Will Shape Future Return Profile

Narrative update Analysts have trimmed their price target on Euroapi by €0.50 to €2.00, citing updated assumptions on revenue growth, profit margins and forward P/E that keep their stance cautious on the shares. Analyst Commentary Recent research has reinforced a cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.00.

EAPI: Lower Profitability Assumptions And New Partnership Will Shape Future Returns

Analysts have trimmed their price target on Euroapi to €2 from €2.50, citing softer assumptions around revenue growth, profit margins and a higher future P/E multiple as the key drivers of the reset. Analyst Commentary Bearish analysts are signalling a cautious stance on Euroapi by aligning around a lower price target of €2, narrowed from €2.50.

EAPI: Higher Discount Rate Will Outweigh Benefits From New Corticosteroid Partnership

Analysts have slightly reduced their Euroapi price target, reflecting a modest reassessment of fair value. This adjustment accounts for a higher discount rate, even as long term profit margin assumptions edge up and revenue declines appear marginally less severe.

Calculating The Intrinsic Value Of Euroapi S.A. (EPA:EAPI)

Dec 18
Calculating The Intrinsic Value Of Euroapi S.A. (EPA:EAPI)

Euroapi S.A. (EPA:EAPI) Not Doing Enough For Some Investors As Its Shares Slump 26%

Dec 18
Euroapi S.A. (EPA:EAPI) Not Doing Enough For Some Investors As Its Shares Slump 26%

Euroapi (EPA:EAPI) Has Debt But No Earnings; Should You Worry?

Oct 03
Euroapi (EPA:EAPI) Has Debt But No Earnings; Should You Worry?

Euroapi S.A. (EPA:EAPI) Just Released Its Interim Results And Analysts Are Updating Their Estimates

Aug 02
Euroapi S.A. (EPA:EAPI) Just Released Its Interim Results And Analysts Are Updating Their Estimates
User avatar

Capacity Expansion And Efficiency Improvements Will Shape Future Success

Euroapi focuses on high-margin differentiated APIs and CDMO services to boost sustainable revenue and profit margins through strategic project expansions.

Analyst Estimates: Here's What Brokers Think Of Euroapi S.A. (EPA:EAPI) After Its Annual Report

Mar 06
Analyst Estimates: Here's What Brokers Think Of Euroapi S.A. (EPA:EAPI) After Its Annual Report

Euroapi S.A.'s (EPA:EAPI) Intrinsic Value Is Potentially 25% Below Its Share Price

Oct 04
Euroapi S.A.'s (EPA:EAPI) Intrinsic Value Is Potentially 25% Below Its Share Price

There's No Escaping Euroapi S.A.'s (EPA:EAPI) Muted Revenues Despite A 32% Share Price Rise

Jul 29
There's No Escaping Euroapi S.A.'s (EPA:EAPI) Muted Revenues Despite A 32% Share Price Rise

Euroapi S.A. (EPA:EAPI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

May 24
Euroapi S.A. (EPA:EAPI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Euroapi (EPA:EAPI) Seems To Be Using A Lot Of Debt

Apr 10
Euroapi (EPA:EAPI) Seems To Be Using A Lot Of Debt

Little Excitement Around Euroapi S.A.'s (EPA:EAPI) Revenues As Shares Take 31% Pounding

Mar 03
Little Excitement Around Euroapi S.A.'s (EPA:EAPI) Revenues As Shares Take 31% Pounding

Euroapi S.A. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts

Mar 02
Euroapi S.A. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts

A Look At The Fair Value Of Euroapi S.A. (EPA:EAPI)

Dec 21
A Look At The Fair Value Of Euroapi S.A. (EPA:EAPI)

Analysts Are Updating Their Euroapi S.A. (EPA:EAPI) Estimates After Its Half-Yearly Results

Aug 04
Analysts Are Updating Their Euroapi S.A. (EPA:EAPI) Estimates After Its Half-Yearly Results

Is Euroapi S.A. (EPA:EAPI) Trading At A 49% Discount?

Aug 02
Is Euroapi S.A. (EPA:EAPI) Trading At A 49% Discount?

Euroapi S.A.'s (EPA:EAPI) Subdued P/S Might Signal An Opportunity

Jun 16
Euroapi S.A.'s (EPA:EAPI) Subdued P/S Might Signal An Opportunity

An Intrinsic Calculation For Euroapi S.A. (EPA:EAPI) Suggests It's 37% Undervalued

Jan 25
An Intrinsic Calculation For Euroapi S.A. (EPA:EAPI) Suggests It's 37% Undervalued

株主還元

EAPIFR PharmaceuticalsFR 市場
7D7.4%-2.0%-1.4%
1Y-50.1%-10.6%1.9%

業界別リターン: EAPI過去 1 年間で-10.6 % の収益を上げたFrench Pharmaceuticals業界を下回りました。

リターン対市場: EAPIは、過去 1 年間で1.9 % のリターンを上げたFrench市場を下回りました。

価格変動

Is EAPI's price volatile compared to industry and market?
EAPI volatility
EAPI Average Weekly Movement8.9%
Pharmaceuticals Industry Average Movement4.0%
Market Average Movement5.3%
10% most volatile stocks in FR Market10.3%
10% least volatile stocks in FR Market2.9%

安定した株価: EAPIの株価は、 French市場と比較して過去 3 か月間で変動しています。

時間の経過による変動: EAPIの weekly volatility ( 9% ) は過去 1 年間安定していますが、依然としてFrenchの株式の 75% よりも高くなっています。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
20202,961David Seignollewww.euroapi.com/en

Euroapi S.A.は、ヒトおよび動物用医薬品の製剤化に使用される医薬品有効成分および中間体の開発、製造、販売、流通を行っている。同社は、固相化学、粒子工学、微生物発酵、低分子合成、プロスタグランジン、ステロイドとホルモン、アヘン剤と規制薬物、脂質を使用する様々なクラスのタイドの受託開発製造組織を提供している。同社は、製薬会社、ジェネリック医薬品メーカー、動物用医薬品メーカー、消費者向け健康・栄養・化粧品メーカー、バイオテクノロジー企業、流通企業、開発・製造受託機関などに製品を提供している。同社は2020年に設立され、フランス・パリに本社を置いている。

Euroapi S.A. 基礎のまとめ

Euroapi の収益と売上を時価総額と比較するとどうか。
EAPI 基礎統計学
時価総額€130.41m
収益（TTM）-€211.20m
売上高(TTM)€852.60m
0.2x
P/Sレシオ
-0.6x
PER（株価収益率

EAPI は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
EAPI 損益計算書（TTM）
収益€852.60m
売上原価€707.70m
売上総利益€144.90m
その他の費用€356.10m
収益-€211.20m

直近の収益報告

Dec 31, 2025

次回決算日

Jul 28, 2026

一株当たり利益（EPS）-2.22
グロス・マージン17.00%
純利益率-24.77%
有利子負債／自己資本比率5.8%

EAPI の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/04/30 18:35
終値2026/04/30 00:00
収益2025/12/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Euroapi S.A. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11

アナリスト機関
Justin Steven SmithBernstein
Patrick Andrew WoodBofA Global Research
Fynn ScherzlerDeutsche Bank